![](https://endpts.com/wp-content/uploads/2017/07/protocols-two.jpg)
Mateon punts failed late-stage cancer drug, axes staffers; Medivir boosted by osteoarthritis data
⇨ The penny stock biotech Mateon Therapeutics $MATN, formerly OxiGene, says it is scrapping a Phase II/III ovarian cancer study of CA4P in combination …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.